When his attempts failed, and his male victim died, he would keep the corpse until it decomposed beyond recognition,  masturbating and performing sexual intercourse on the body. He would perform sexual activities before and after murdering his victims. Dahmer explained that he only killed his victims because he did not want them to leave. More modern necrophiliacs include Scottish serial killer Dennis Nilsen, and English David Fuller, who is considered the worst offender of this kind in English legal history.Havelock Ellis, in his 1903 volume of Studies of the Psychology of Sex, believed that necrophilia was related to algolagnia, in that both involve the transformation of a supposed negative emotion, such as anger, fear, disgust, or grief, into sexual desire. Classification
In the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), recurrent, intense sexual interest in corpses can be diagnosed under Other Specified Paraphilic Disorder (necrophilia) when it causes marked distress or impairment in important areas of functioning.Forensic Psychologist Anil Aggrawal introduced a ten tier classification of necrophiliacs based on increasing severity of disorder. Additionally, criminologist Lee Mellors typology of homicidal necrophiliacs consists of eight categories (A–H) and is based on the combination of two behavioural axes: destructive (offender mutilates the corpse for sexual reasons) – preservative (offender does not), and cold (offender used the corpse sexually two hours or more after death) – warm (offender used the corpse sexually less than two hours after death). This renders four categories (A-D) to which Mellor adds an additional four (E-H):

Category A (cold/destructive), e.g.
Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. Lixisenatide received FDA approval on July 28, 2016.In 2010, Zeland and Sanofi extended their license agreement to allow Sanofi to develop a combination therapy of lixisenatide with insulin glargine, which was Sanofis best selling drug at the time, with sales of around €3 billion in 2009. Sanofi planned to start the Phase III trial that year. Sanofi submitted the NDA in December 2015 for the combination, called LixiLan and it was considered by the same Endocrinologic and Metabolic Drugs Advisory FDA Committee that was considering lixisenatide as a single agent. In May 2016 by a vote of 12–2, with several members of the committee expressing reservations about Sanofis plans to offer two pens with different ratios of insulin glargine and lixisenatide - one for people who had never taken insulin before and one for people who had; there was also concern about how to handle dosing when switching people from a single drug regimen to the combination drug. In August 2016 the FDA told Sanofi that it was delaying a final decision for three months, and asked Sanofi for more data on how people used the delivery devices.Patent protection for lixisenatide expires in 2020. References
External links
"Lixisenatide". Drug Information Portal. U.S. National Library of Medicine.